Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Bristol-Myers Squibb
AstraZeneca
Eisai Inc.
PMV Pharmaceuticals, Inc
Mayo Clinic
Dartmouth-Hitchcock Medical Center
H. Lee Moffitt Cancer Center and Research Institute
NeoImmuneTech
National Cancer Institute (NCI)
Genmab
Tubulis GmbH
Sumitomo Pharma America, Inc.
Bristol-Myers Squibb
Genmab
NEC Bio B.V
Yale University
Ohio State University Comprehensive Cancer Center
Exscientia AI Limited
Nanjing Leads Biolabs Co.,Ltd
AstraZeneca
Gilead Sciences
Radiopharm Theranostics, Ltd
Onchilles Pharma Inc
Ocellaris Pharma, Inc.
Dana-Farber Cancer Institute
Apollo Therapeutics Ltd
Big Ten Cancer Research Consortium
Seagen Inc.
H. Lee Moffitt Cancer Center and Research Institute
Transgene
Avenzo Therapeutics, Inc.
BicycleTx Limited
Pfizer
BicycleTx Limited
Volastra Therapeutics, Inc.
Strand Therapeutics Inc.
M.D. Anderson Cancer Center
ITM Oncologics GmbH
Immunitas Therapeutics
Maastricht University Medical Center
University of Kansas Medical Center
Hadassah Medical Organization
Scancell Ltd
CytoDyn, Inc.
Texas Tech University Health Sciences Center
A2 Biotherapeutics Inc.
Harbin Medical University
TCR2 Therapeutics